You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

Cediprof Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for CEDIPROF INC, and what generic and branded alternatives to CEDIPROF INC drugs are available?

CEDIPROF INC has four approved drugs.



Summary for Cediprof Inc
US Patents:0
Tradenames:4
Ingredients:4
NDAs:4

Drugs and US Patents for Cediprof Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cediprof Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 210754-002 Jul 5, 2022 DISCN No No ⤷  Sign Up ⤷  Sign Up
Cediprof Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET;ORAL 208737-003 Feb 1, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up
Cediprof Inc METHYLPHENIDATE HYDROCHLORIDE methylphenidate hydrochloride TABLET;ORAL 208737-002 Feb 1, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-012 Dec 8, 2003 AB1,AB2,AB3 RX No No ⤷  Sign Up ⤷  Sign Up
Cediprof Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 210754-004 Jul 5, 2022 DISCN No No ⤷  Sign Up ⤷  Sign Up
Cediprof Inc DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate TABLET;ORAL 210754-005 Jul 5, 2022 DISCN No No ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Cediprof Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-005 Mar 1, 2002 6,399,101 ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-006 Mar 1, 2002 6,399,101 ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-001 Mar 1, 2002 6,399,101 ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-007 Mar 1, 2002 6,399,101 ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-011 Mar 1, 2002 6,399,101 ⤷  Sign Up
Cediprof Inc LEVO-T levothyroxine sodium TABLET;ORAL 021342-003 Mar 1, 2002 6,399,101 ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.